BioWorld

May 11, 2004

View Archived Issues

Guilford Begins Phase III Program For Aquavan Injection In Sedation

Guilford Pharmaceuticals Inc. on Monday said it initiated a Phase III development program for Aquavan Injection, a candidate for procedural sedation. (BioWorld Today) Read More

Cell Genesys Receives GVAX SPA For Phase III Prostate Cancer Trial

Read More

Peptimmune Gets License To Obesity Drug From Genzyme

Read More

Other News To Note

Read More

Appointments And Advancements

Read More